AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Tennessee

SB2149

Relative to clinical trials

Status

Enacted

114th General Assembly (2025-2026)

IntroducedDate TBC (done)
PassedApr 23, 2026 (done)
SignedMay 22, 2026 (done)
Law in effectMay 22, 2026 (done)

Sponsor: Page Walley (Republican)
Type: Clinical Research
Substances: Psilocybin
Session dates: January 14, 2025 – April 23, 2026

Official text

Summary (from PoliPsy)

As introduced, enacts the "Helping Open Pathways to Effective (HOPE) Treatment Act." - Amends TCA Title 9; Title 33; Title 53; Title 63 and Title 68.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: wapp.capitol.tn.gov

Legislative history

May 27, 2026
Assigned Public Chapter 1119
May 22, 2026
Signed by Governor
May 5, 2026
Enrolled (Passed Both Chambers)
April 15, 2026
Engrossed (Passed One Chamber)
February 2, 2026
Introduced

Loading bill…